TKMR News Alert Tekmira Pharmaceuticals Corp (TKMR) 24.68 01/12/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 12, 2015 at 5:52 PM

Tekmira Pharmaceuticals Corp (TKMR) 24.68 $TKMR

Bristol-Myers and Tiffany are big market movers
AP - 1 hr 8 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
FMI: 46.74 (+22.81), SHPG: 209.10 (-8.39), BBW: 21.75 (+3.12), TKMR: 24.68 (+8.98), NPSP: 45.35 (+3.44), TIF: 89.01 (-14.44), BMY: 62.18 (+1.86), CVX: 105.88 (-2.33), TKM.TO: 29.38 (+10.55)

Tekmira Purchases OnCore Biopharma To Find Hep B Cure
at Investor's Business Daily - Mon Jan 12, 12:49PM CST
Tekmira Pharmaceuticals (TKMR) stock soared on Monday after the Canadian drugmaker said Sunday that it would buy privately held OnCore Biopharma to bolster its efforts to develop a cure for hepatitis B. The merged company has the potential to become...
TKMR: 24.68 (+8.98)

Nasdaq stocks posting largest percentage increases
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AGEN: 6.17 (+0.88), CLUB: 7.19 (+0.93), EVOK: 7.52 (+0.82), SCYX: 14.50 (+1.66), TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST

CLUB: 7.19 (+0.93), FRO: 4.63 (+0.69), NES: 3.20 (-1.09), ARWR: 6.90 (-2.16), BBW: 21.75 (+3.12), TKMR: 24.68 (+8.98), NADL: 1.25 (-0.16), TIF: 89.01 (-14.44), BITA: 74.04 (-15.07), CPXX: 2.78 (+0.37), AGEN: 6.17 (+0.88), TOPS: 1.49 (+0.24), IRMD: 15.88 (+2.48), FMI: 46.74 (+22.81), SRPT: 11.91 (-2.04), REXX: 2.94 (-0.74), LOCM: 0.74 (-0.32), BLFS: 2.10 (-0.17), SNDK: 83.57 (-13.47), AWX: 3.15 (+0.27)

Today's Market: Pharma And Biotech M&A Start 2015 With A Bang
Matthew Smith - at Seeking Alpha - Mon Jan 12, 9:13AM CST

ABC: 90.93 (-2.07), FMI: 46.74 (+22.81), MWIV: 190.00 (+14.35), GILD: 101.21 (-1.00), SHPG: 209.10 (-8.39), TKMR: 24.68 (+8.98), NPSP: 45.35 (+3.44), ABBV: 65.76 (-0.02)

Tekmira teams up with OnCore to focus on hepatitis B cure
By The Associated Press - AP - Mon Jan 12, 8:52AM CST
Shares of Tekmira Pharmaceuticals soared Monday after the Canadian drugmaker said it would buy privately held OnCore Biopharma to form a team focused on developing a hepatitis B cure.
GILD: 101.21 (-1.00), TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

Tekmira Pharmaceuticals (TKMR) Stock Soars After OnCore Biopharma Acquisition Announcement
at The Street - Mon Jan 12, 8:50AM CST
Shares of Tekmira Pharmaceuticals (TKMR) surged in morning trading Monday after the company agreed to acquire OnCore Biopharma to shift focus to developing hepatitis B virus treatments.
TKMR: 24.68 (+8.98)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST

EYES: 11.75 (+0.91), ZIOP: 5.93 (+0.55), OIBR: 2.16 (-0.41), ARWR: 6.90 (-2.16), TKMR: 24.68 (+8.98), SN: 8.56 (-0.32), TIF: 89.01 (-14.44), NBG: 1.66 (+0.09), BMY: 62.18 (+1.86), LULU: 62.59 (+3.96), CPXX: 2.78 (+0.37), AGEN: 6.17 (+0.88), GDP: 2.85 (-0.39), FMI: 46.74 (+22.81), ASNA: 11.44 (-0.20), NPSP: 45.35 (+3.44), AMCO: 1.90 (+0.34), SNDK: 83.57 (-13.47)

Tekmira/Oncore Merger Represents Substantial Upside
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Mon Jan 12, 7:49AM CST
Well, one IPO we were eagerly awaiting is no longer on this year's docket with Tekmira (NASDAQ: TKMR )'s merger agreement with Oncore announced tonight all plans for any anticipated IPO this year are now null and void. However, we believe TKMR will...
GBIM: 7.49 (-0.34), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), ARWR: 6.90 (-2.16), SHPG: 209.10 (-8.39), TKMR: 24.68 (+8.98)

Wall Street Breakfast: Week Begins With Healthcare Deals
Wall Street Breakfast - at Seeking Alpha - Mon Jan 12, 5:31AM CST

TSLA: 202.21 (-4.45), BIIB: 347.84 (+5.50), F: 15.22 (+0.01), TKMR: 24.68 (+8.98), RBS: 11.13 (-0.01), K: 65.48 (-0.95), JNJ: 104.58 (-0.36), SPY: 202.65 (-1.60), QQQ: 101.55 (-1.07), FMI: 46.74 (+22.81), SHPG: 209.10 (-8.39), TSEM: 13.33 (-0.10), GPRE: 22.31 (-0.58), GM: 35.84 (+0.25), ABBV: 65.76 (-0.02), NDAQ: 47.35 (-1.15), BABA: 101.62 (-1.40)

Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company
Thomson Reuters ONE - Sun Jan 11, 9:09PM CST
Transaction Highlights:
TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

Tekmira merges with firm developing HBV cure
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 8:55PM CST

TKMR: 24.68 (+8.98)

J&J Starts Ebola Vaccine Study, Updates Production Goal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 5:00PM CST
Johnson & Johnson (JNJ) commenced a phase I study on a preventive Ebola vaccine to evaluate the safety and tolerability of the Ebola vaccine regimen.
JNJ: 104.58 (-0.36), TKMR: 24.68 (+8.98), GSK: 42.93 (+0.13)

Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:20PM CST
Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
TKMR: 24.68 (+8.98), AMGN: 156.22 (+0.49), AMAG: 42.32 (-0.12)

Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 43.44 (+0.40), JNJ: 104.58 (-0.36), NVO: 43.70 (+0.49), OGXI: 2.30 (+0.01), GILD: 101.21 (-1.00), ONVO: 6.69 (-0.33), TKMR: 24.68 (+8.98), TEVA: 57.01 (+0.29), MDXG: 8.79 (-0.48)

Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.54 (+0.02), TKMR: 24.68 (+8.98), ARNA: 5.65 (+0.22), DYAX: 14.41 (+0.12), XOMA: 3.73 (+0.07)

Rewards Outweigh Risks: Research Reports on Walgreens, Tekmira, RedHill, Verso, and Pacific Ethanol
PR Newswire - Fri Jan 02, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Walgreens (NASDAQ: WBA), Tekmira (NASDAQ: TKMR), RedHill (NASDAQ: RDHL), Verso (NYSE: VRS), and Pacific Ethanol (NASDAQ: PEIX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
WBA: 75.70 (+0.03), RDHL: 14.91 (+0.66), VRS: 3.17 (-0.18), TKMR: 24.68 (+8.98), PEIX: 8.43 (-1.04)

Meadowbrook and NephroGenex are big market movers
AP - Wed Dec 31, 3:15PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
REN: 0.81 (-0.03), TKMR: 24.68 (+8.98), CVEO: 3.28 (+0.02), CVX: 105.88 (-2.33), MIG: 8.35 (-0.02), TKM.TO: 29.38 (+10.55)

Tekmira Pharmaceuticals (TKMR) Stock Surges Today After Clinical Study Update
at The Street - Wed Dec 31, 1:42PM CST
Shares of Tekmira Pharmaceuticals (TKMR) spiked Wednesday after the company provided an update on a Phase I/II clinical study.
TKMR: 24.68 (+8.98)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

USFCR Wins 2026 Award for Federal Contracting Services

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Veteran Marketer Joins The Wisory's Advisory Board

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Crystal Risotti: Leading IT Compliance in Healthcare

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...